Non-pharmaceutical Motion Sickness Mitigation

Not Applicable

Completed

• Conditions: Healthy
• Interventions: Device: Galvanic Vestibular Stimulation

• Registration Number: NCT04859868
• Lead Sponsor: Mayo Clinic

Brief Summary

The purpose of this study is evaluate the effect of timing and magnitude on the administration of our nonpharmaceutical treatment to motion sickness, and to evaluate the effect of Galvanic Vestibular Stimulation (GVR) amplitude on functional fitness task performance.

Detailed Description

Not available

Study Timeline

• Study Start: 2021-03-12
• Study First Submitted: 2021-04-01
• Study First Submitted QC: 2021-04-23
• Study First Posted: 2021-04-26
• Primary Completion: 2022-08-30
• Study Completion: 2022-08-30
• Results First Submitted: 2023-06-14
• Status Verified: 2023-09
• Results First Submitted QC: 2023-09-27
• Last Update Submitted: 2023-09-27
• Results First Posted: 2023-09-28
• Last Update Posted: 2023-09-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

• Must be able to consent to participate themselves.
• Must be able to attend in-person sessions at the Mayo Aerospace Medicine and Vestibular Research Laboratory in Scottsdale, AZ.
• No racial ethnic groups will be excluded.
• Must be fluent speakers of English.

Read More

Exclusion Criteria

• History of vestibular disease, migraine, or significant balance disorder.
• Traumatic brain injury.
• Recent middle ear infection or recent motion sickness (within 72 hours).
• History of severe motion sensitivity.
• Women who are pregnant.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Galvanic Vestibular Stimulation During the Entire Session	Galvanic Vestibular Stimulation	Subjects given Galvanic Vestibular Stimulation (GVS) to mitigate motion sickness in the rotating chair turning stimulation ON from beginning.
Galvanic Vestibular Stimulation Starting From Mid-session	Galvanic Vestibular Stimulation	Subjects given Galvanic Vestibular Stimulation (GVS) to mitigate motion sickness in the rotating chair turning stimulation ON from the middle of the session.

Primary Outcome Measures

Name	Time	Method
Motion Perception	During the rotation of the chair, approximately 1 hr	Motion Perception verbal report using a visual analog scale (1-100) will be recorded during the rotation of the chair (1=feeling no motion perception; 100=feeling the maximum motion perception)

Secondary Outcome Measures

Name	Time	Method
Motion Sickness Questionnaire	During the rotation of the chair, approximately 1 hr	subjective experiences of motion sickness in a scale of 0-10 (0=not at all; 10=most severe)

Trial Locations

Locations (1)

Mayo Clinic in Arizona; 🇺🇸 Scottsdale, Arizona, United States